Clinical Trials Without Borders: The Evolution of Global Drug Development

Clinical trials are the foundation of modern drug development, serving as the primary method for evaluating the safety and efficacy of new medical treatments before they reach patients. By systematically assessing how drugs, biologics, and medical devices perform under controlled conditions, clinical trials generate the critical data necessary for regulatory approvals and subsequent commercialization. These trials follow a phased approach, beginning with early-stage safety assessments in a small group of participants and culminating in large-scale studies designed to confirm efficacy, monitor side effects, and compare new treatments against existing standards of care. Over time, the design and execution of clinical trials have evolved to improve efficiency and patient access, and in recent decades, this evolution has accelerated with the increasing globalization of the clinical research enterprise.^1,2

The globalization of clinical trials refers to the expansion of trial activities beyond historically dominant regions, such as North America and Western Europe, into a broader range of geographic locations. While international collaboration in medical research has existed for decades, globalization in the modern sense began to take shape in the late 20th century as pharmaceutical companies and research institutions sought to access more diverse patient populations, reduce costs, and expedite drug development timelines. Advances in regulatory harmonization, particularly through initiatives like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), have facilitated this shift by establishing common standards for conducting and reporting trials across multiple jurisdictions.^3,4 As a result, clinical trials today are routinely conducted across multiple continents, with increasing participation from emerging markets in Asia, Latin America, and Africa.⁵

Despite the advantages of global clinical trials — including improved patient recruitment, enhanced diversity in study populations, and expanded access to medical innovations — this trend has introduced new challenges. Ethical concerns surrounding informed consent, post-trial access to treatments, and the potential exploitation of low-income populations remain pressing issues. Additionally, variations in regulatory requirements between countries create logistical and compliance hurdles, complicating trial design and execution.^1,6 More recently, political and economic shifts, such as changes in global funding priorities and the post-pandemic regulatory landscape, have further influenced the conduct of international clinical research.^5,7

Formalized approaches to testing medical interventions began to emerge in the 18th and 19th centuries. One of the earliest recorded clinical trials was James Lind’s scurvy experiment in 1747, which compared different treatments for sailors suffering from the disease. Over time, controlled studies became more sophisticated, with the introduction of placebo controls and randomization in the early 20th century marking significant methodological advancements.⁸

As scientific methods improved, so too did international collaboration in medical research. The mid-20th century saw a rise in multinational clinical trials, particularly as pharmaceutical companies sought to introduce new therapies to multiple markets. However, this period was also marred by ethical violations, most notably the Tuskegee syphilis study and human experimentation conducted without informed consent during World War II. These abuses led to the development of formal ethical guidelines, including the Nuremberg Code (1947) and the Declaration of Helsinki (1964), which emphasized voluntary participation and the necessity of informed consent.^1,2

The establishment of Good Clinical Practice (GCP) guidelines in the 1970s and 1980s further standardized ethical and procedural requirements for conducting trials. GCP set clear expectations for trial design, monitoring, and reporting, with an emphasis on protecting patient rights and ensuring data integrity. By the late 20th century, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had strengthened oversight of clinical trials, paving the way for more structured global research collaborations.^3,9

The 1990s and early 2000s marked a significant turning point in the globalization of clinical trials. As pharmaceutical companies faced rising costs and longer development timelines in traditional research hubs in the United States and Western Europe, they increasingly turned to emerging markets where trials could be conducted more efficiently. Lower operational costs, faster patient recruitment, and treatment-naïve populations made countries such as India, China, and Eastern European nations attractive locations for clinical research.⁴

A key milestone in this period was the establishment of the ICH in 1990, which aimed to unify regulatory standards across major markets, including the United States, Europe, and Japan. The ICH’s development of common guidelines for trial conduct (ICH E6: GCP) facilitated more seamless multinational studies by reducing regulatory discrepancies between regions.³

Regulatory agencies played an increasing role in shaping global trial conduct. The FDA introduced policies allowing data from foreign trials to be used in U.S. regulatory submissions, provided they adhered to GCP standards.⁹ The EMA similarly emphasized harmonized trial data requirements across Europe, improving the efficiency of multinational studies. These regulatory shifts encouraged global collaboration and enabled pharmaceutical companies to design trials with international patient populations from the outset, rather than limiting studies to single-country cohorts.⁸

Case studies from this period illustrate the growing globalization trend. The Clinical Trials Directive (2001/20/EC) in Europe sought to streamline multinational trials, while major pharmaceutical firms expanded their trial footprints into emerging economies.¹⁰ For example, large-scale cardiovascular trials in India demonstrated the feasibility of conducting complex studies outside of traditional Western markets, further accelerating global trial expansion.²

The last decade has seen even greater globalization of clinical trials, driven by advancements in technology, regulatory reforms, and the rise of new research hubs. China, India, Brazil, and South Korea have become central players in clinical development, benefiting from government investment in research infrastructure and streamlined regulatory pathways.⁵ The increasing complexity of drug development, particularly in areas such as oncology and rare diseases, has also necessitated larger and more diverse patient pools, further incentivizing multinational trial designs.¹¹

One of the most significant developments has been the emergence of digitalization and decentralized clinical trials (DCTs). Digital tools, including electronic data capture (EDC) systems, telemedicine, and wearable monitoring devices, have enabled trials to reach patients across geographically dispersed locations without requiring them to travel to centralized sites. This shift has not only improved patient access and retention but also made trials more feasible in remote or underdeveloped regions.⁷

The COVID-19 pandemic accelerated global coordination in clinical research, with vaccine trials demonstrating the ability to rapidly launch and conduct large-scale, multinational studies. Regulatory agencies adopted more flexible approaches to trial oversight, including adaptive trial designs and rolling regulatory reviews, which have persisted beyond the pandemic as sponsors seek greater efficiency in clinical development.⁵

As the globalization of clinical trials continues to evolve, emerging challenges — including geopolitical shifts, funding changes, and regulatory fragmentation — will shape the future of cross-border research collaborations.

One of the most significant advantages of global clinical trials is the ability to enroll diverse patient populations more efficiently. Recruiting participants is one of the most time-consuming and costly aspects of conducting a trial, with many studies in developed markets struggling to meet enrollment targets. Expanding trials to multiple countries allows sponsors to access larger pools of eligible patients, reducing recruitment timelines and expediting study completion.

Beyond recruitment speed, globalization enhances the genetic and demographic diversity of clinical trial populations, improving the generalizability of results. Historically, many trials were conducted primarily in North America and Europe, leading to drug approvals based on data from predominantly Caucasian populations. This limited diversity has resulted in gaps in understanding how treatments perform across different ethnicities, age groups, and socioeconomic backgrounds. By including patients from Asia, Latin America, and Africa, global trials help ensure that approved therapies are effective and safe for broader populations.⁷

Regulatory agencies have increasingly recognized the importance of diverse representation in clinical research. The FDA, for instance, has issued guidance encouraging sponsors to conduct trials that reflect real-world patient demographics. Similarly, initiatives in Europe and Asia promote the inclusion of historically underrepresented populations in drug development.⁵ These efforts highlight the growing recognition that a truly globalized clinical trial ecosystem is essential for developing equitable and effective medical treatments.

The financial benefits of conducting trials across multiple regions are another major driver of globalization. Drug development costs have risen sharply, with estimates placing the total cost of bringing a new therapy to market at well over $2 billion. Conducting trials in emerging markets often provides a cost advantage, as labor, facility, and patient care expenses are significantly lower compared with North America and Western Europe.¹²

Another cost-related benefit is the availability of treatment-naïve patients. In developed countries, many patients have already been exposed to multiple lines of treatment, making it difficult to find individuals who meet strict trial inclusion criteria. In contrast, emerging markets often have large populations of treatment-naïve patients, particularly for diseases such as oncology, cardiovascular conditions, and infectious diseases. Access to these populations not only speeds up recruitment but also allows for cleaner efficacy and safety data, as results are not confounded by prior treatment effects.¹¹

Moreover, operational efficiencies in emerging markets can lead to faster study execution. Many countries have streamlined regulatory pathways to attract foreign sponsors, and in some cases, site initiation and ethics approvals are processed more quickly than in highly regulated regions such as the United States or the European Union. This contributes to shorter overall trial durations, reducing the time required to bring new therapies to market.⁷

Global clinical trials also provide strategic advantages in regulatory approvals and market access. Some regulatory agencies, particularly in Asia, offer expedited approval pathways for drugs that have been tested in local populations. For example, China's National Medical Products Administration (NMPA) has implemented reforms to facilitate the acceptance of foreign trial data, provided that Chinese patients were included in the study. This policy allows sponsors to conduct trials in multiple regions while ensuring they meet local regulatory requirements for approval.⁵

Additionally, globalization enables pharmaceutical companies to pursue simultaneous drug development and registration in multiple markets. Historically, new therapies were often introduced in the United States or Europe first before expanding to other regions. This sequential approach delayed patient access in many parts of the world. Today, multinational trials allow sponsors to seek approvals in multiple jurisdictions simultaneously, accelerating global drug availability. Regulatory initiatives such as the Project Orbis program, which facilitates parallel oncology drug reviews across multiple regulatory agencies, further support this trend.¹²

Beyond logistical and financial benefits, the globalization of clinical trials has fostered scientific advancements and innovation. Cross-border collaboration allows researchers from different regions to contribute expertise, improving trial design and execution. By leveraging the strengths of diverse research institutions, sponsors can enhance data quality, ensure greater standardization in trial methodologies, and implement best practices from multiple regulatory environments.⁷

Real-world evidence and post-marketing surveillance also benefit from global trials. Once a drug is approved, ongoing monitoring of its safety and efficacy across different populations is critical. Conducting studies in multiple countries provides a more comprehensive data set for post-market analysis, helping regulators and healthcare providers understand long-term treatment effects. This is particularly relevant for rare diseases and conditions where patient populations are geographically dispersed, requiring multinational efforts to generate meaningful data.⁵

While the globalization of clinical trials offers numerous benefits, it also introduces complex challenges that must be carefully managed to ensure trial success. These challenges span regulatory, logistical, operational, and ethical domains, requiring sponsors to develop robust strategies to navigate them effectively.

One of the most significant obstacles in global clinical trials is the variation in regulatory requirements across different jurisdictions. The approval timelines and submission processes differ considerably between agencies such as the FDA, the EMA, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and China’s NMPA (formerly CFDA). These differences create a fragmented regulatory landscape that can delay trial initiation and complicate the approval of trial designs that need to comply with multiple sets of rules simultaneously.^11,13

Managing compliance with varying regulations requires significant coordination between trial sponsors, regulatory affairs teams, and local authorities. Some agencies, such as the EMA, have sought to streamline multinational trial approvals through initiatives like the Clinical Trials Regulation (CTR) 536/2014, which aims to harmonize the process across European Union member states. However, other regions still maintain independent regulatory frameworks, forcing sponsors to tailor their trial applications to multiple systems, often resulting in delays and added costs.⁶

Further complicating the regulatory landscape is the increasing scrutiny around data privacy and patient protection laws. Regulations such as the General Data Protection Regulation (GDPR) in Europe impose strict requirements on how patient data is collected, stored, and shared. These requirements can create compliance hurdles when trials involve multiple regions with differing data protection standards.²

Beyond regulatory challenges, global trials require careful planning to overcome logistical and operational difficulties, particularly when conducting studies in developing regions. Selecting appropriate trial sites is a critical decision that can impact recruitment rates, data quality, and overall trial success. While emerging markets offer cost advantages and treatment-naïve patient populations, they may lack the infrastructure and trained personnel required to conduct trials according to international standards.¹⁴

Standardizing protocols across different trial sites presents another challenge. Differences in medical practices, diagnostic tools, and patient management approaches can introduce variability in trial execution, making it difficult to ensure consistency across sites. Sponsors must invest in robust training programs for investigators and site personnel to maintain uniform adherence to protocols, which can be resource-intensive.¹¹

The supply chain for investigational products is also a major consideration. Transporting and storing investigational drugs, particularly biologics and cell and gene therapies that require strict temperature controls, is significantly more complex in regions with limited cold-chain infrastructure. Delays in product shipment, customs clearance issues, and supply shortages can all impact trial timelines and data integrity.⁶

Maintaining data integrity in global clinical trials is essential for regulatory approval and scientific validity. However, conducting trials across multiple sites with varying levels of experience can lead to inconsistencies in data collection, reporting, and adherence to protocol requirements. Differences in healthcare infrastructure and EDC capabilities can further complicate efforts to ensure high-quality, reliable data.¹³

Risk-based monitoring (RBM) and remote monitoring approaches have gained traction as solutions to these challenges. RBM allows sponsors to focus resources on high-risk sites and activities, rather than conducting traditional full-site monitoring visits. Advances in digital technologies, such as wearable sensors and telemedicine, also offer new opportunities to enhance data collection while reducing the need for frequent on-site monitoring. However, integrating these technologies across global trial sites remains a challenge, particularly in regions with limited internet connectivity or healthcare IT infrastructure.¹¹

Cultural and linguistic differences present additional hurdles in global trials, particularly in obtaining informed consent and ensuring patient understanding of trial procedures. In some regions, there is skepticism toward clinical research due to historical abuses or distrust of foreign pharmaceutical companies. These perceptions can impact patient recruitment and retention, necessitating culturally sensitive community engagement efforts to build trust.⁶

Language barriers further complicate the informed consent process. Regulatory guidelines require that informed consent documents be provided in a language understandable to participants, but direct translations do not always capture the nuances of medical terminology or the risks associated with participation. In some cases, patients may agree to participate without fully understanding the implications, raising ethical concerns.²

To address these issues, sponsors must work closely with local investigators, ethics committees, and community leaders to ensure that study information is communicated effectively and in a culturally appropriate manner. Employing multilingual study coordinators and utilizing audiovisual consent processes can help mitigate language-related challenges and improve patient comprehension.¹⁴

The globalization of clinical trials has introduced significant ethical challenges, particularly in ensuring the protection of participants across diverse regions with varying levels of healthcare access, regulatory oversight, and societal norms. Ethical concerns center around obtaining valid informed consent, ensuring equitable distribution of trial benefits, and maintaining rigorous ethical oversight, particularly in trials conducted in low-income and developing countries. Addressing these issues is critical to upholding the ethical integrity of global clinical research.

Obtaining valid informed consent is a cornerstone of ethical clinical research, yet it remains a complex issue in multinational trials. Participants must fully understand the risks, benefits, and purpose of the study before enrolling, but in many global trials, this standard is difficult to achieve due to barriers such as low literacy levels, cultural dynamics, and potential coercion.¹ In low-income regions, patients may perceive participation in a clinical trial as their only access to medical care, leading to consent that is technically voluntary but ethically questionable.

Cultural factors also influence how informed consent is obtained and understood. In some societies, medical decisions are made collectively by family members or community leaders rather than by the individual alone. This dynamic can complicate traditional consent models based on Western ethical frameworks that prioritize individual autonomy.⁹ Additionally, language barriers and poor translation of medical terminology can result in participants agreeing to study participation without fully grasping the implications.²

Several historical cases have highlighted ethical failures in obtaining proper informed consent, with one of the most infamous being the AZT trials in Africa in the 1990s. In these trials, researchers tested a shorter, cheaper course of AZT, an antiretroviral drug used to prevent mother-to-child HIV transmission. Critics argued that these trials exploited African participants by using placebo controls instead of the standard long-course AZT treatment that was already established as effective. The controversy underscored the ethical dilemma of applying different standards in clinical trials based on economic or geographic factors.¹⁴

Another major ethical concern in global trials is the equitable distribution of benefits. When clinical trials are conducted in lower-income regions, participants often contribute valuable data that leads to drug approvals in wealthier nations. However, these same participants may struggle to access the approved therapies once the trial is completed. Ensuring post-trial access to medications is a key ethical obligation, yet many trials fail to provide clear mechanisms for continued patient treatment.¹²

To mitigate this issue, some regulatory bodies and advocacy groups have pushed for stronger commitments from sponsors to provide post-trial access to successful therapies, particularly in cases where the studied drug addresses an urgent medical need. The World Medical Association’s Declaration of Helsinki emphasizes the responsibility of researchers to ensure that participants in developing countries are not left without access to effective treatments after trials conclude.^3,15 Despite these guidelines, disparities in post-trial access remain a persistent challenge in global research.

Additionally, ethical concerns arise regarding the potential exploitation of low-income populations in clinical research. The lower cost of conducting trials in emerging markets has incentivized pharmaceutical companies to outsource studies to these regions, sometimes without sufficient safeguards to ensure that participants are not subjected to undue risk. The ethical principle of justice requires that the burdens and benefits of research be distributed fairly, yet in many cases, the communities hosting clinical trials see little long-term benefit from their participation.^1,9

Ethical oversight in clinical trials is typically managed by Institutional Review Boards (IRBs) or local ethics committees, which are responsible for ensuring that studies comply with ethical standards and regulatory requirements. However, oversight mechanisms vary widely between high-income and low-income countries, leading to inconsistencies in how ethical protections are enforced.²

In wealthier nations, IRBs operate within well-established regulatory frameworks, often with stringent requirements for trial design, informed consent, and risk assessment. In contrast, some developing countries lack robust ethical review infrastructure, which can result in trials being approved with minimal scrutiny. In some cases, ethics committees may lack independence due to financial or institutional pressures, raising concerns about conflicts of interest.³

Efforts to strengthen ethical review processes globally have included initiatives such as the WHO’s research ethics training programs and the establishment of regional ethics networks that provide guidance and capacity-building for ethics committees in developing regions. However, challenges remain in ensuring uniform ethical oversight across all trial locations, particularly as the number of multinational studies continues to grow.¹²

The globalization of clinical trials has necessitated the development of regulatory frameworks that facilitate multi-regional research while maintaining ethical and scientific rigor. Over the past several decades, regulatory bodies have worked toward harmonization to streamline trial execution across different regions, though challenges remain in achieving full alignment. Key milestones, including the establishment of GCP guidelines, regulatory adaptations to international research, and major policy changes in regions such as the United States, Europe, and China, have shaped the current regulatory landscape.

One of the most significant developments in global clinical trial regulation was the formation of ICH in 1990. This organization was established to create uniform regulatory guidelines across major markets, with the goal of reducing redundancy in trial requirements and improving the efficiency of multinational studies.³

A key outcome of this effort was the adoption of ICH E6 (Good Clinical Practice) guidelines, which established a globally accepted standard for designing, conducting, recording, and reporting clinical trials.¹⁶ ICH E6 outlined principles for protecting trial participants, ensuring data integrity, and defining sponsor and investigator responsibilities. The harmonization of these guidelines allowed for smoother execution of global trials by reducing discrepancies between national regulatory requirements.¹¹

Harmonization efforts have significantly improved the feasibility of conducting trials across multiple countries by providing a common regulatory framework. However, despite these advances, some regional differences persist, requiring sponsors to navigate unique regulatory landscapes depending on their target markets.¹²

To accommodate the increasing globalization of drug development, regulatory agencies have adapted their policies to better integrate foreign clinical trial data into their review processes. One of the most notable examples is the U.S. FDA’s acceptance of foreign clinical data under 21 CFR 312.120.17 This regulation allows the FDA to consider data from non-U.S. trials as long as they adhere to GCP and provide sufficient evidence that the trial design, patient population, and endpoints are applicable to the U.S. market.⁴

Similarly, regulatory bodies in Europe and China have taken steps to facilitate global trials. The EMA has worked to streamline its approval processes for multinational trials, reducing bureaucratic delays. In China, the NMPA has reformed its clinical trial approval system, leading to a significant increase in international trial participation. Previously known for its long approval timelines, China has implemented new policies allowing foreign trial data to be used for regulatory submissions, provided that Chinese patients are included in the study.¹⁸

Japan’s PMDA, however, has faced unique challenges in multi-regional trials. Historically, Japan has required local clinical data for drug approval, creating additional hurdles for global sponsors seeking market access. Though the PMDA has made progress in aligning with ICH standards, the requirement for “bridging studies” to establish efficacy in Japanese patients has remained a barrier to full global integration.⁸

Several landmark regulatory changes have shaped the global clinical trial landscape, reinforcing the commitment to ethical and scientific rigor while improving trial efficiency. One of the most significant changes in Europe was the adoption of the European Clinical Trials Regulation (CTR) 536/2014.¹⁹ This regulation, which came into effect in 2022, replaced the previous Clinical Trials Directive and introduced a centralized system for trial approvals across EU member states. The primary goal was to reduce administrative burdens, accelerate study start-up times, and improve transparency in clinical research.¹²

At the global level, the World Health Organization (WHO) has played an important role in setting ethical and regulatory standards for clinical trials, particularly in low- and middle-income countries. The WHO’s guidelines emphasize the need for ethical review processes, equitable participant protection, and post-trial access to approved therapies. These efforts have helped establish frameworks for conducting clinical research in regions with historically weaker regulatory oversight, ensuring that trials adhere to ethical best practices.³

The globalization of clinical trials does not occur in isolation—it is shaped by broader political, economic, and technological forces that influence where and how research is conducted. In recent years, the industry has undergone significant transformations, driven by regulatory adaptations post-COVID, shifting global research funding priorities, and the emergence of new clinical trial hubs in Asia. Additionally, evolving investment trends in biopharma have reshaped the types of therapies receiving global trial funding, particularly in areas such as precision medicine and rare diseases.

The COVID-19 pandemic triggered sweeping regulatory changes, many of which have persisted beyond the immediate public health crisis. One of the most significant shifts was the increased adoption of DCTs, which allowed sponsors to conduct research more flexibly by integrating telemedicine, remote patient monitoring, and digital endpoints. Regulators relaxed certain requirements during the pandemic to facilitate trial continuity, and many of these adaptations have now been formalized in updated regulatory guidance.⁵

In addition to DCTs, there has been a surge in the use of artificial intelligence (AI) and real-world data to enhance trial efficiency. AI is being applied to patient recruitment, protocol optimization, and risk-based monitoring, helping sponsors design more targeted and efficient trials. Real-world data, including electronic health records and wearable sensor data, is being increasingly incorporated into clinical trial designs to provide more comprehensive patient insights.⁷

Another major regulatory shift post-COVID has been the expanded use of Emergency Use Authorizations (EUAs). The unprecedented speed at which COVID-19 vaccines and therapeutics were developed and approved demonstrated the potential for accelerated regulatory pathways. While EUAs are primarily intended for public health emergencies, the success of these expedited approvals has sparked discussions about whether similar frameworks could be adapted for high-priority, non-pandemic-related drugs, such as novel oncology treatments or gene therapies.¹²

The defunding of the United States Agency for International Development (USAID) and other global health research initiatives has had ripple effects across the clinical trial ecosystem, particularly in lower-income regions that rely on public-sector funding for medical research. USAID has historically played a major role in supporting vaccine development, infectious disease trials, and public health interventions. Its recent budget cuts have led to the suspension of several key programs, including malaria and HIV vaccine trials, forcing researchers to seek alternative funding sources.

In response, emerging economies have stepped in to fill the funding gap. China, India, and several Gulf nations have significantly increased their investments in biomedical research, offering new opportunities for clinical trial sponsors. For example, China’s aggressive push into biotech innovation has included government subsidies for drug development, as well as streamlined regulatory pathways to attract global sponsors. Additionally, Brazil and South Korea, among other countries, have positioned themselves as attractive clinical trial destinations by offering tax incentives and infrastructure development grants for biopharma companies.⁶

China has rapidly emerged as a dominant force in global clinical trials, overtaking Europe in some key research areas. The country has made substantial investments in clinical trial infrastructure, including the expansion of GCP-certified research sites and the development of a more flexible regulatory framework. Reforms by the NMPA have made it easier for foreign pharmaceutical companies to conduct trials in China, provided that local patient populations are included in the studies.⁵

By contrast, Europe’s role in global clinical trials has declined. Between 2013 and 2023, Europe’s share of global commercial clinical drug trials dropped from 22% to 12%, a shift attributed to bureaucratic hurdles, slow regulatory approvals, and increased competition from Asia. The introduction of CTR 536/2014 was intended to streamline the EU’s trial approval process, but some experts argue that implementation challenges have slowed progress rather than accelerating trial execution.⁴

Other Asian markets, including South Korea, India, and Singapore, are also gaining prominence as clinical trial hubs. These countries offer fast-track regulatory pathways, high-quality research infrastructure, and cost advantages that attract global sponsors. South Korea, for example, has positioned itself as a leader in oncology trials, while India has become a key player in vaccine and infectious disease research.⁷

The focus of global clinical trial funding is shifting toward rare diseases, precision medicine, and advanced therapeutics, reflecting broader trends in biopharma innovation. The rise of gene therapies, cell therapies, and mRNA-based treatments has led sponsors to seek more targeted patient populations for clinical trials, often requiring global recruitment efforts to find eligible participants.¹²

At the same time, there is growing interest in Latin America and Africa as emerging clinical trial regions. Historically, these regions have been underutilized due to infrastructure limitations, but recent investments in research capabilities and regulatory modernization have made them more attractive. Latin America, in particular, is seeing increased clinical trial activity due to high patient enrollment rates, treatment-naïve populations, and lower operational costs.¹³

Africa is also gaining recognition as a key region for infectious disease research and vaccine trials, especially in light of past successes with malaria and Ebola vaccine development. However, concerns remain about ethical oversight and the need for stronger local regulatory frameworks to ensure that trials are conducted to international standards.⁶

The globalization of clinical trials continues to evolve, driven by advancements in technology, regulatory developments, shifting industry priorities, and increasing ethical scrutiny. As clinical research becomes more complex, sponsors and regulators are exploring new models to improve efficiency, inclusivity, and transparency. Trends, such as decentralized trials, artificial intelligence-driven analytics, and global regulatory harmonization, are expected to shape the future of multinational clinical trials. At the same time, ethical and equity considerations remain at the forefront, as stakeholders work to ensure fair access to research participation and treatment benefits.

DCTs and hybrid models, which incorporate both site-based and remote study components, are becoming integral to global research strategies. The expansion of telemedicine, home-based clinical assessments, and wearable technology is reducing the reliance on traditional trial sites, making it easier to recruit and retain diverse patient populations across multiple regions.⁵ By reducing geographic and logistical barriers, these models allow for more inclusive participation, particularly among patients in remote or underserved areas.

The adoption of digital endpoints, which rely on real-time data from wearable sensors and remote monitoring devices, is further transforming trial designs. These tools provide continuous physiological and behavioral data, offering more detailed insights into treatment effects while minimizing the need for frequent in-person visits. This approach has been particularly valuable in therapeutic areas such as neurology and cardiovascular disease, where objective, real-world data collection can enhance study outcomes.⁷

Despite these benefits, challenges remain in scaling decentralized trial models globally. Internet connectivity, healthcare infrastructure, and regulatory acceptance of digital tools vary widely between countries. Additionally, ensuring data security and patient privacy remains a critical concern as more sensitive health information is collected and transmitted remotely.⁶

Efforts to create a truly global regulatory framework for clinical trials have gained momentum as multinational studies become the norm. While organizations like the ICH have made significant strides in aligning regulatory requirements, inconsistencies remain across key markets. Industry leaders and regulators are increasingly advocating for mutual recognition agreements, which would allow trial data generated in one country to be more easily accepted in others, reducing redundancy and accelerating approvals.⁵

I and machine learning are also playing an expanding role in regulatory decision-making. AI-assisted trial design, including predictive analytics for patient recruitment and risk-based monitoring, is improving the efficiency of multinational studies. These tools can analyze vast datasets to optimize protocol designs, identify high-risk study sites, and predict regulatory approval timelines based on historical trends. As AI technologies become more sophisticated, their integration into clinical trial governance could further standardize and streamline global research efforts.⁷

Despite these advances, geopolitical factors, including trade policies and nationalistic regulatory approaches, pose potential obstacles to seamless global trial execution. Some nations have implemented stricter requirements for local data generation before granting approvals, challenging the notion of a fully harmonized regulatory system.

The globalization of clinical trials is also being shaped by shifting pharmaceutical industry priorities, particularly increased collaboration with government agencies and non-profit organizations. In recent years, there has been a growing emphasis on public–private partnerships (PPPs) to support clinical research in areas of high unmet need, such as rare diseases, antimicrobial resistance, and global pandemics.⁵

Governments and non-profits are playing a more active role in funding and facilitating multinational trials, particularly in low- and middle-income countries where industry investment alone may not be sufficient. The success of global COVID-19 vaccine trials demonstrated the effectiveness of cross-sector collaboration, and similar models are now being applied to other urgent public health challenges.⁷

Pharma companies are also increasing their focus on precision medicine and personalized therapies, which require highly targeted patient populations. This shift is driving demand for global trials that recruit participants based on genetic, molecular, or biomarker-driven criteria, rather than traditional geographic considerations. As a result, new trial designs are incorporating more flexible and adaptive methodologies to efficiently evaluate these therapies across diverse populations.⁶

The globalization of clinical trials has reshaped the landscape of drug development, enabling sponsors to accelerate patient recruitment, enhance data diversity, and optimize cost efficiency. Over the past several decades, regulatory harmonization efforts, advancements in trial design, and the emergence of new research hubs in Asia, Latin America, and Africa have driven this transformation. However, along with these benefits come significant challenges, including complex regulatory requirements, logistical barriers, ethical concerns, and geopolitical shifts that influence where and how clinical research is conducted.

As the industry moves forward, several key trends will define the future of global clinical trials. The adoption of decentralized and hybrid trial models, supported by telemedicine and real-world data collection, is making studies more accessible to broader patient populations. Advances in AI and predictive analytics are improving trial efficiency and regulatory decision-making, while greater collaboration between pharmaceutical companies, governments, and non-profit organizations is addressing unmet medical needs in both high- and low-income regions.

Despite these advancements, maintaining ethical integrity in global trials remains paramount. Ensuring that participants provide fully informed consent, protecting vulnerable populations from exploitation, and securing post-trial access to treatments are ongoing concerns that require stronger regulatory frameworks and industry accountability. Additionally, efforts to improve trial diversity and inclusion must continue, as underrepresentation in clinical research can lead to disparities in drug efficacy and safety across different demographics.

The future of global clinical trials will be shaped by a delicate balance between innovation, ethics, and accessibility. While technological and regulatory advancements have the potential to make trials more efficient and inclusive, they must be implemented in ways that prioritize patient rights and data integrity. By fostering transparency, collaboration, and regulatory alignment, the industry can ensure that clinical research continues to drive medical progress while upholding the highest ethical and scientific standards. As trials become more global in scope, the responsibility of sponsors, regulators, and researchers to maintain these principles will be greater than ever.

Our parent company, That’s Nice, is committed to supporting the companies and innovators driving the next wave of pharma and biotech innovation. To celebrate That’s Nice’s 30th anniversary, Pharma’s Almanac is diving into 30 groundbreaking advancements, trends, and breakthroughs that have shaped the life sciences, highlighting the industry-defining milestones our agency has had the pleasure of growing alongside. Here’s to 30 years of innovation and the future ahead!

1. da Silva, Riccardo Eccard, et al. “Globalization of clinical trials: ethical and regulatory implications.” International Journal of Clinical Trials. 3:1–8 (2016).

2. George, Melvin and Steven Aibor Dkhar. “Globalization of Clinical Trials – Where are We Heading?” Current Clinical Pharmacology. 13 Aug. 2016.

3. Karlberg, Johan PE. “Globalization of sponsored clinical trials.” Nature Reviews Drug Discovery. 7:458 (2008).

4. Tierney, Garth and Silvia Zieher. “Key Strategies for Effective Globalization of Clinical Trials.” Pharmaceutical Outsourcing. Accessed 14 Mar. 2025.

5. Izarn, F, et al. “Globalization of clinical trials in oncology: a worldwide quantitative analysis.” ESMO Open. 10: 104086 (2025).

6. Alemayehu, Chalachew, Geoffrey Mitchell, and Jane Niles. “Barriers for conducting clinical trials in developing countries- a systematic review.” International Journal for Equity in Health. 17: 37 (2018).

7. Jenei, Kristina, Fabio Y Moraes, and Bishal Gyawali. “Globalisation of clinical trials in oncology: a double-edged sword?” BMJ Oncology. 29 Sep. 2023.

8. Tassignon, Jean-Pierre. “The Globalization of Clinical Trials.” Applied Clinical Trials. 1 Jan. 2006.

9. Li, Rebecca, et al. “Global Clinical Trials: Ethics, Harmonization and Commitments to Transparency.” Harvard Public Health Review. May 2015.

10. Clinical trials - Directive 2001/20/EC. European Commission. 31 Jan. 2022.

11. Jeong, Sohyun, et al. “Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013.” Trials. 18:288 (2017).

12. Eichler, Hans-George and Fergus Sweeney. “The evolution of clinical trials: Can we address the challenges of the future?” Clinical Trials. 15(1 Suppl): 27–32 (2018).

13. Glickman, Seth, et al. “Ethical and Scientific Implications of the Globalization of Clinical Research.” N. Eng. J. Med. 360:816-823 (2009).

14. Ladin, Zvi. “Globalization of Clinical Trials: Promise and Reality.” Boston Medtech Advisors. Nov. 2008.

15. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Participants. World Medical Association. 13 Dec. 2024.

16. ICH E6 Good clinical practice - Scientific guideline. European Medicines Agency. Accessed 14 Mar. 2025.

17. 21 CFR 312.120 - Foreign clinical studies not conducted under an IND. Food and Drug Administration. Accessed 14 Mar. 2025.

18. Mardini, Ali, et al. “Global Disparities in Access to Vaccine Clinical Trials: A Review of the Literature.” Vaccines. 12:348 (2024). h

19. Clinical trials - Regulation EU No 536/2014. European Commissoin. 31 Jan 2022.